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ABSTRACT
Introduction There is growing concern about the 
aggressiveness of cancer care at the end of life (ACCEoL), 
defined as overly aggressive treatments that compromise 
the quality of life at its end. Recognising the most affected 
patients is a cornerstone to improve oncology care. Our 
aim is to identify factors associated with ACCEoL for 
patients with cancer dying in hospitals.
Methods All adult patients with cancer who died in public 
hospitals in mainland Portugal (January 2010 to December 
2015), identified from the hospital morbidity database. This 
database provided individual clinical and demographic 
data. We obtained hospital and region- level variables from 
a survey and National Statistics. The primary outcome is 
a composite ACCEoL measure of 16 indicators. We used 
multilevel random effects logistic regression modelling 
(p<0·05).
Results We included 92 155 patients: median age 73 
years; 62% male; 53% with metastatic disease. ACCEoL 
prevalence was 71% (95% CI 70% to 71%). The most 
prevalent indicators were >14 days in the hospital (43%, 
42–43) and surgery (28%, 28–28) in the last 30 days. 
Older age (p<0·001), breast cancer (OR 0·83; 95% CI 0·76 
to 0·91), and metastatic disease (0·54; 95% CI 0·50 to 
0·58) were negatively associated with ACCEoL. In contrast, 
higher Deyo- Charlson Comorbidity Index (p<0·001), 
gastrointestinal and haematological malignancies 
(p<0·001), and death at cancer centre (1·31; 95% CI 1·01 
to 1·72) or hospital with medical oncology department 
(1·29; 95% CI 1·02 to 1·63) were positively associated 
with ACCEoL. There was no association between hospital 
palliative care services at the hospital of death and 
ACCEoL.
Conclusion Clinical factors related to a better 
understanding of disease course are associated with 
ACCEoL reduction. Patients with more comorbidities and 
gastrointestinal malignancies might represent groups 
with complex needs, and haematological patients may 
be at increased risk because of unpredictable prognosis. 
Improvement of hospital palliative care services could 
help reduce ACCEoL, particularly in cancer centres and 
hospitals with medical oncology department, as those 
services are usually under- resourced, thus reaching few.
INTRODUCTION
Towards the end of life (EoL), patients with 
cancer wish to feel comfortable, be treated 
with dignity and achieve a sense of comple-
tion.1 They also wish to avoid overly aggressive 
treatments, which can compromise symptom 
control and advance care planning.2 Appro-
priate management of EoL care has been 
raised as a quality- of- care issue and indica-
tors have been developed to identify health 
systems that apply overly intensive treatments 
Key questions
What is already known about this subject?
 ► There is growing concern about the aggressiveness 
of cancer care at the end of life (ACCEoL), defined as 
overly aggressive treatments that compromise the 
quality of life.
 ► The end of life period most studied in relation to 
ACCEoL is the last month of life, for which Earle et 
al6 identified key ACCEoL indicators, expanded by 
Luta et al.12
 ► Recognising the most affected patients is a corner-
stone to improve this public health unmet need.
What does this study add?
 ► Unchanged trend of high ACCEoL in a European 
country (Portugal)—7 out of 10 patients with cancer.
 ► Most prevalent indicators: >14 days in hospital and 
surgery in last 30 days of life.
 ► Older age, breast cancer and metastatic disease 
were associated with lower ACCEoL.
 ► Comorbidities, gastrointestinal and haematological 
cancers with higher ACCEoL.
How might this impact on clinical practice?
 ► Clinicians should consider cancer type, disease 
stage, comorbidities, age and the influence of hos-
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for terminal advanced cancer patients with very limited 
clinical benefit, defined as aggressiveness of cancer care 
at the EoL (ACCEoL).3 As one component of EoL, the 
ACCEoL is interconnected with deleterious effects for 
patients and families such as worse quality of life and 
bereavement outcomes.4 5 This led to growing concern 
across societies about the ACCEoL.6–11
Earle et al6 reported one of the first ACCEoL studies, 
based on administrative data measuring key indicators 
within the last month of life, including overuse of chemo-
therapy (new regimen within 30 days, or any administra-
tion within 14 days before death), underuse of hospice 
care, and high rates of emergency room visits, hospitalisa-
tion or intensive care unit (ICU) admissions. They found 
that each indicator was present in less than one- third of 
patients but also that ACCEoL prevalence was increasing 
in the 90s in the USA.6 Studies followed in other coun-
tries, interestingly with different findings.7–11 Luta et al12 
proposed an expanded list of ACCEoL measures based 
on a systematic review.
Despite these advances in ACCEoL research, the issue 
remains neglected yet vital for clinical oncology, in face 
of the growing number of people dying with cancer.13 
Despite two- thirds of the population express a preference 
to die at home in a scenario of advanced cancer14 and 
increases in several nations on the percentage of cancer 
patients dying at home rather than in hospital,15 still many 
patients remain increasingly exposed to other ACCEoL 
indicators, such as ICU admission.16 The rise of hospital 
deaths in other countries suggests a level of dependency 
on hospital resources and of ACCEoL which are contrary 
to people’s preferences.14 17–19
Recognising the profile of patients at risk of receiving 
ACCEoL is critical for better understanding this public 
health unmet need and improving oncology care. Our 
study aims to identify factors associated with ACCEoL for 
cancer patients dying in hospitals.
METHODS
Study design and setting
This is a nationwide retrospective cohort study of adults 
who died with cancer in Portuguese hospitals. The study 
followed the REporting of studies Conducted using Obser-
vational Routinely- collected health Data statement.20
Patients
We included all patients that: (1) died in a public 
hospital in mainland Portugal between January 2010 and 
December 2015; (2) were aged ≥18 years at the time of 
death and (3) had a diagnosis of cancer recorded in the 
episode leading to death, using International Classifica-
tion of Diseases, ninth Revision, Clinical Modification 
(ICD-9- CM) codes from the chapter ‘neoplasms’ (codes 
140–239), excluding benign neoplasms, carcinoma in 
situ, neoplasms of uncertain behaviour or unspecified 
nature (210-239).
Primary outcome
Study outcome is a composite binary measure of ACCEoL, 
positive in the presence of at least one of 16 individual 
indicators (S1 - online supplemental file 1). The list of 
indicators from Earle et al6 was expanded based on the 
systematic review by Luta et al.12 A national expert panel 
assessed content validity. For all patients, all indicators 
were measured for the last 30 days of life, except the use 
of chemotherapy and immunotherapy/biological agents, 
which was shortened to the last 14 days of life, following 
Earle et al’s criteria.6
Data sources
We used the hospital morbidity database (HMD) to iden-
tify patients and obtain individual- level data. The HMD 
contains routinely- collected data from all public hospitals 
in mainland Portugal for funding purposes, since 1989.21 
The dataset was anonymised by the Portuguese Health 
System Central Administration and included: (1) demo-
graphic data: sex, age at death and borough of residence; 
(2) clinical data coded by ICD-9- CM: metastatic disease 
status, procedures and main or secondary diagnoses used 
for the calculation of the Deyo- Charlson Comorbidity 
Index (DCCI)— used to predict mortality that derives 
from the sum of the score attributed to each comorbidity 
out of 17 chronic medical conditions22 23 and (3) admin-
istrative data: date of admission, discharge or death, type 
of treatment (medical vs surgical) and hospital of death.
In September 2016, we surveyed all hospital administra-
tion boards and directors of palliative care services (PCS) 
created before January 2016. Following recommendations 
from a Cochrane Review on methods to increase response 
to postal and electronic questionnaires,24 we obtained a 
78% response rate. We used a semistructured question-
naire to obtain the following information: (1) hospital: 
hospital type (general vs cancer centre), hospital dimen-
sion (number of beds), existence of medical oncology 
department (MOD); (2) PCS: existence and creation 
date, existence of palliative care unit and number of beds. 
We made follow- up contacts and consulted the national 
directory of PCS to complete missing data. Hospital- level 
data were linked to individual- level data by hospital of 
death variable from HMD.
We obtained lists of boroughs classified by health 
region, urbanisation level (predominantly urban, mid- 
urban, predominantly rural) based on Census 2011 data 
and by deprivation level based on Census 2001 data 
(European Deprivation Index).25 Region- level data were 
linked to individual and hospital- level data by borough of 
residence variable from HMD.
Statistical analysis
We first described the study population, comparing 
the characteristics of patients who received ACCEoL 
with those that did not, using Pearson’s χ2 or Mann- 
Whitney tests. We then determined the prevalence of the 
composite measure of ACCEoL and each individual indi-















pen: first published as 10.1136/esm







3Martins- Branco D, et al. ESMO Open 2020;5:e000953. doi:10.1136/esmoopen-2020-000953 Martins- Branco D, et al. ESMO Open 2020;5:e000953. doi:10.1136/esmoopen-2020-000953
status, primary cancer site and type of hospital of death. 
We examined trends in composite and individual indica-
tors from 2010 to 2015, using χ2 test for trend. We consid-
ered a difference of >5% as clinically meaningful.
Taking the composite ACCEoL measure as the depen-
dent variable, unadjusted odds ratio (ORs) with 95% 
confidence interval (CI) were calculated for each inde-
pendent variable. We used multilevel random effects 
logistic regression modelling (accounting for individual, 
hospital and region levels), including year of death and 
all independent variables that showed association with 
ACCEoL on unadjusted analysis. Finally, we conducted 
a subgroup analysis for patients with metastatic disease. 




We included 92 155 patients (S2 - online supplemental file 
1), 62% male and median age of 73 years (interquartile 
range - IQR, 62–81). Fifty- three percent had metastatic 
disease and the most common primary solid tumour sites 
were lung (16%) and colorectal (10%). Twelve percent 
had haematological malignancies. The median DCCI 
score was eight points (IQR, 4–9). Only 15% died in a 
cancer centre but nearly all patients died in a hospital 
with MOD (93%). Most (66%) died in a hospital with 
hospital PCS (hPCS). The characteristics of the groups 
with and without ACCEoL were statistically different at: 
i) individual- level: all variables except year of death; ii) 
hospital- level: hPCS, MOD, hospital type, hospital dimen-
sion, health region; and iii) region- level: palliative care 
unit beds/100 deaths- year (table 1).
PCS resources
Survey results showed that the percentage of hospital 
centres with hPCS increased from 42% (13/31) in 2010 
to 74% (23/31) in 2015 (p<0·05), reflected in an increase 
of the percentage of patients who died in hospitals with 
hPCS (50% in 2010 to 82% in 2015, p<0·001) (S3 - online 
supplemental file 1).
ACCEoL prevalence
The prevalence of the composite ACCEoL measure was 
71% (95% CI 70% to 71%). The difference by meta-
static disease status was only 3% (patients with meta-
static disease: 70% vs others: 73%). ACCEoL also varied 
by primary cancer site (63% in breast cancer to 79% in 
haematological malignancies) and type of hospital of 
death (74% in cancer centre vs 69% in general hospital) 
(S4 - online supplemental file 1).
The most prevalent indicators were >14 days of length 
of stay in hospital (43%, 95% CI 42 to 43) and surgery 
(28%, 95% CI 28 to 28) within the last 30 days, with no 
clinically meaningful differences between patients with 
versus without metastatic disease except for ICU admis-
sion (4% vs 10%, respectively), mechanical ventilation 
(2% vs 8%) and insertion of endotracheal tube (15% vs 
22%) (figure 1).
The primary outcome remained stable overtime (from 
71% in 2010 to 72% in 2011) and despite some indica-
tors showing statistically significant changes from 2010 to 
2015, none were considered clinically meaningful (S5 - 
online supplemental file 1).
Factors associated with ACCEoL
In multivariate analysis, older age (p<0·001), breast 
cancer (OR 0·83; 95% CI 0·76 to 0·91), and metastatic 
disease (OR 0·54; 95% CI 0·50 to 0·58) were negatively 
associated with ACCEoL. In contrast, higher DCCI 
(p<0·001), gastrointestinal and haematological malig-
nancies (p<0·001), and death at a cancer centre (OR 
1·31; 95% CI 1·01 to  1·72) or at a hospital with MOD (OR 
1·29; 95% CI 1·02 to  1·63) were positively associated with 
ACCEoL. Adjusting for confounders, there was no asso-
ciation between existence of hPCS and ACCEoL. There 
was a contextual effect of hospital- level with a median OR 
of 1·20 (95% CI 1·15 to 1·27), but no effect of region 
(S6 - online supplemental file 1). The subgroup analysis 
of patients with metastatic disease showed also a negative 
association with ACCEoL for male sex (OR 0·93, 95% CI 
0·88 to 0·98) and cancer as main diagnosis of last hospital 
admission (OR 0·88, 95% CI 0·83 to 0·94), and a positive 
association for year of death (OR 1·03, 95% CI 1·01 to 
1·05) (table 2).
DISCUSSION
Our study showed an unchanged trend of high preva-
lence of ACCEoL in a European country. Seven out of 10 
adult cancer patients dying in Portuguese public hospitals 
between 2010 and 2015 received ACCEoL, more than in 
other Western countries (71% vs 22%–65%).6 7 10 26
The high rate of hospitalisation may reflect not only the 
intensity of clinical care, but also the extent of social and 
clinical support in community and home settings. Free 
access to the National Health Service for cancer patients 
facilitates hospitalisation in a context of scarce commu-
nity support. This should be considered when estab-
lishing comparisons with different health systems, where 
the prevalence of the most common individual indicator 
of our study, >14 days in hospital within the last month 
of life, was lower (43% vs 11%–30%).6 9 On the other 
hand, we found ICU admission prevalence at the bottom 
of the previously reported range (6% vs 3%–25%)5–9 and 
less prevalent in patients with metastatic disease (4% vs 
10%), suggesting that the reduced use of limited and 
merely clinically driven hospital resources may reflect an 
adequate intensity of clinical care, despite the high rate of 
ACCEoL mainly due to hospitalisation.
However, more than one- fourth of the patients were 
submitted to a surgical intervention at the EoL, the most 
common procedure and the second most prevalent 
individual indicator. Although palliative surgical inter-
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Patients who died 
with ACCEoL
(n=65 564)








Sex (% male) 61.9 62.2 61.2 χ2
p=0.004
Ageat death Median in years 
(IQR)
73 (62–81) 72 (61–80) 75 (65–83) M- W p<0.001
  18–39 (%) 2.0 2.3 1.1 M- W p<0.001
  40–49 (%) 5.2 5.7 4.0
  50–59 (%) 13.1 13.9 11.1
  60–69 (%) 21.4 22.5 18.7
  70–79 (%) 29.5 29.8 28.6
  80–89 (%) 24.7 22.5 29.9
  ≥90 (%) 4.3 3.3 6.6
Primary cancer 
type
Lung (%) 15.9 14.4 16.5 χ2p<0.001
Colorectal (%) 10.2 9.5 8.6
Gastric (%) 8.7 8.5 6.7
Prostate (%) 8.5 6.7 9.8
Breast (%) 5.8 4.7 7.1
Haematological (%) 11.9 12.4 8.0
Other (%) 41.3 43.7 43.4
Deyo- Charlson Comorbidity Index, 
median score (IQR)
8 (4–9) 8 (4–9) 8 (4–9) M- W NS
Less than mild: 2 
(%)
11.6 10.4 14.3 M- W p<0.001
Mild: 3–4 (%) 16.1 15.9 16.7
Moderate: 5–6 (%) 8.2 8.8 6.9
Severe:>6 (%) 64.1 64.9 62.1
Cancer as main diagnosis of last 
hospital admission (%)
65.9 66.8 63.6 χ2p<0.001
Metastatic disease (%) 53.0 52.1 55.4 χ2p<0.001
Year of death (%) 2010 16.0 15.9 16.1 M- W NS
2011 16.4 16.5 16.2
2012 16.4 16.4 16.3
2013 16.8 16.9 16.7
2014 17.0 17.0 17.1
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Patients who died 
with ACCEoL
(n=65 564)








Hospital palliative care service (% yes) 65.8 67.2 62.5 χ2p<0.001
Median years of existence (IQR) 4.6 (2.3–8.6) 4.6 (2.4–8.4) 4.6 (2.2–9.0) M- W NS
Quartile 1 (0.003–2.3 years) (%) 16.5 16.5 16.5 χ2p<0.001
Quartile 2 (2.3–4.6 years) (%) 16.4 17.1 14.8
Quartile 3 (4.6–8.6 years) (%) 16.5 17.0 15.2
Quartile 4 (8.6–23.0 years) (%) 16.4 16.7 15.9
Medical oncology department (% yes) 92.9 93.5 91.6 χ2p<0.001
Hospital type (% cancer centre) 14.7 15.2 13.4 χ2p<0.001
Hospital dimension, median no. beds 
(IQR)
380 (319–568) 380 (319–570) 380 (319–565) M- W p=0.011
Quartile 1 (6–319 beds) (%) 29.7 30.3 28.3 M- W p<0.001
Quartile 2 (320–380 beds) (%) 21.0 20.2 22.8
Quartile 3 (381–568 beds) (%) 24.5 23.6 26.5
Quartile 4 (568–1299 beds) (%) 24.8 25.8 22.4
Health region (HR) Lisbon and Tagus 
Valley (%)
40.8 41.4 39.4 χ2p<0.001
North (%) 31.4 30.5 33.8






Palliative care unit beds, median no of 









Quartile 1 (0–0.8) (%) 29.8 29.5 30.4 χ2p<0.001
Quartile 2 (0.8–1.0) (%) 22.4 22.2 23.2
Quartile 3 (1.0–1.2) (%) 23.5 24.1 22.1
Quartile 4 (1.2–19.4) (%) 24.3 24.2 24.4
Home palliative care services (% yes) 11.6 11.5 11.8 NS
Median years of existence (IQR) 5.3 (2.3–15.8) 5.5 (2.3–15.8) 4.9 (2.2–15.6) NS
  Quartile 1 (0.003–2.3 years) (%) 2.9 2.8 3.0 NS
  Quartile 2 (2.3–5.4 years) (%) 2.9 2.8 3.0
  Quartile 3 (5.4–15.9 years) (%) 2.9 2.9 2.9
  Quartile 4 (15.9–59.8 years) (%) 2.9 3.0 2.7









Quartile 1 (least deprived: −7.31 to 
−2.34) (%)
25.5 25.6 25.2 NS
Quartile 2 (-2.34 to −1.24) (%) 24.5 24.5 24.6
Quartile 3 (-1.24 to −0.01) (%) 25.0 24.8 25.4
Quartile 4 (most deprived: −0.01 to 
13.47) (%)
25.0 25.1 24.8
Urbanisation level Predominantly 
urban (%)
69.0 69.0 68.8 NS
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primary tumour resection procedure with curative intent 
might be causes, further studies should focus on this indi-
vidual outcome. We found a relatively low prevalence of 
chemotherapy administration in the last 14 days of life, 
compared with previous reports (7% vs 2%–24%).6–9 
However, this indicator might be underestimated since it 
did not measure the administration of oral agents.
Breast cancer was the primary cancer type associated 
with the lowest rate of ACCEoL, probably due to better 
knowledge of clinical trajectories of disease subtypes. On 
the other hand, we found that patients with gastrointes-
tinal and haematological malignancies are at increased 
risk of ACCEoL. In patients with gastrointestinal malig-
nancies, it may be due to higher rate of postoperative 
complications in early stages and digestive haemorrhage 
or malignant obstructions in late stages.26 Patients with 
haematological malignancies represent a subgroup with 
more unpredictable prognosis and higher percentage of 
curative intent treatments, and therefore, as previously 
reported,7 10 associated with higher ACCEoL. Also as 
previously reported,6 7 patients with higher DCCI were at 
increased risk of ACCEoL, certainly related with higher 
complexity of care. As expected, patients with metastatic 
disease were less likely to experience ACCEoL, mainly 
when cancer was the main diagnosis of last hospital 
admission, suggesting that hospitalisation due to late 
stage disease progression is recognised. Despite trends 
remaining unchanged in the overall sample, ACCEoL is 
increasing over time in metastatic disease. This might be 
explained by the scientific advances on systemic antineo-
plastic treatments, mostly experienced in advanced stages. 
Aligned with literature,7 9 age was the most influential 
Figure 1 Prevalence of composite and individual indicators of ACCEoL (%), overall and by disease stage. ACCEoL, 
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Adjusted (subgroup of 
patients with metastatic 
disease) (n=31 199)




Sex (female—reference) 92 155   
Male 57 071 1.04 (1.01 to 1.08) <0.01 0.97 (0.93 to 1.01) 0.12 0.93 (0.88 to 0.98) 0.01
Age at death (in years) 92 155   
18–39 1 800 Reference <0.001 Reference <0.001 Reference <0.001
40–49 4 790 0.71 (0.61 to 0.81) 0.81 (0.68 to 0.97) 0.78 (0.62 to 0.97)
50–59 12 038 0.61 (0.54 to 0.70) 0.70 (0.59 to 0.82) 0.65 (0.53 to 0.80)
60–69 19 745 0.59 (0.52 to 0.67) 0.65 (0.55 to 0.76) 0.57 (0.47 to 0.70)
70–79 27 147 0.51 (0.45 to 0.58) 0.54 (0.46 to 0.63) 0.48 (0.39 to 0.59)
80–89 22 718 0.37 (0.33 to 0.42) 0.40 (0.34 to 0.46) 0.36 (0.29 to 0.44)
≥90 3 917 0.25 (0.22 to 0.28) 0.27 (0.23 to 0.32) 0.23 (0.18 to 0.30)
Primary cancer type 92 155   
Lung 14 695 Reference <0.001 Reference <0.001 Reference <0.001
Colorectal 9 419 1.27 (1.19 to 1.34) 1.55 (1.44 to 1.67) 1.17 (1.07 to 1.28)
Gastric 8 024 1.45 (1.36 to 1.54) 1.73 (1.60 to 1.87) 1.47 (1.33 to 1.62)
Prostate 7 825 0.81 (0.77 to 0.86) 1.04 (0.97 to 1.13) 1.08 (0.97 to 1.20)
Breast 5 346 0.77 (0.72 to 0.82) 0.83 (0.76 to 0.91) 0.72 (0.65 to 0.80)
Haematological 11 013 1.77 (1.67 to 1.88) 1.73 (1.60 to 1.87) ·
Other 38 046 1.13 (1.08 to 1.17) 1.29 (1.23 to 1.36) 1.12 (1.04 to 1.20)
Deyo- Charlson Comorbidity 
Index
92 155   
Less mild: 2 10 646 Reference <0.001 Reference <0.001 · ·
Mild: 3–4 14 864 1.31 (1.24 to 1.38) 1.31 (1.22 to 1.40) ·
Moderate: 5–6 7 590 1.73 (1.62 to 1.84) 1.68 (1.54 to 1.84) ·
Severe:>6 59 055 1.43 (1.37 to 1.49) 2.20 (2.02 to 2.38) ·
Cancer as main diagnosis 
of last hospital admission 
(no—reference)
92 155   
Yes 60 732 1.15 (1.12 to 1.19) <0.001 1.04 (0.99 to 1.08) 0.10 0.88 (0.83 to 0.94) <0.001
Metastatic disease 
(no—reference)
92 155   
Yes 48 870 0.88 (0.85 to 0.90) <0.001 0.54 (0.51 to 0.58) <0.001 · ·
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factor on ACCEoL, with the oldest patients having 73% 
lower odds of receiving ACCEoL compared with the 
youngest. Male sex in metastatic patients was associated 
with decreased risk of ACCEoL, a disparity not clearly 
understood and the opposite of the reported in other 
continents,7 27 maybe resulting from cultural differences.
Considering environmental factors, death at a cancer 





Adjusted (subgroup of 
patients with metastatic 
disease) (n=31 199)





Hospital palliative care 
service
67 262
No existence 23 001 Reference <0.001 Reference 0.18 Reference 0.42
0.003–2.3 years of existence 11 075 1.15 (1.09 to 1.20) 1.02 (0.94 to 1.11) 1.02 (0.92 to 1.13)
2.3–4.6 years of existence 11 038 1.32 (1.26 to 1.39) 1.10 (1.00 to 1.22) 1.09 (0.96 to 1.23)
4.6–8.6 years of existence 11 076 1.28 (1.22 to 1.34) 1.05 (0.92 to 1.18) 1.02 (0.87 to 1.18)




62 465   
Yes 58 055 1.31 (1.23 to 1.40) <0.001 1.29 (1.02 to 1.63) 0.03 1.26 (0.98 to 1.62) 0.07
Hospital type
(General hospital—reference)
92 155   
Cancer centre 13 536 1.16 (1.12 to 1.21) <0.001 1.31 (1.01 to 1.72) 0.04 1.38 (1.04 to 1.83) 0.03
Hospital dimension 57 683   
6–319 beds 17 156 Reference <0.001 Reference 0.20 Reference 0.10
320–380 beds 12 104 0.83 (0.79 to 0.87) 1.11 (1.00 to 1.24) 1.12 (0.99 to 1.28)
381–568 beds 14 123 0.83 (0.79 to 0.87) 1.08 (0.96 to 1.24) 1.14 (0.98 to 1.32)





Palliative care unit beds* 92 155   
0–0.8 beds/100 deaths, per HR 27 427 Reference <0.01 Reference 0.24   Reference 0.13
0.8–1.0 beds/100 deaths, per 
HR
20 687   0.96 (0.91 to 1.00) 0.97 (0.92 to 1.02) 0.95 (0.88 to 1.02)
1.0–1.2 beds/100 deaths, per 
HR
21 675   1.13 (1.08 to 1.18) 1.05 (0.97 to 1.12) 1.10 (1.00 to 1.21)
1.2–19.4 beds/100 deaths, 
per HR
22 366   0.98 (0.94 to 1.02) 0.96 (0.88 to 1.04) 0.94 (0.84 to 1.05)
Home palliative care team 92 155   
No existence 81 438 Reference 0.06 · · · ·
0.003–2.3 years of existence 2 662   0.93 (0.85 to 1.01) · ·
2.3–5.4 years of existence 2 663   0.92 (0.85 to 1.00) · ·
5.4–15.9 years of existence 2 662   1.00 (0.91 to 1.08) · ·
15.9–59.8 years of existence 2 660   1.07 (0.98 to 1.17) · ·
European Deprivation Index 85 688   
least deprived: −7.31 to −2.34 21 830 Reference 0.41 · · · ·
−2.34 to −1.24 21 024   0.98 (0.94 to 1.02) · ·
−1.24 to −0.01 21 415   0.96 (0.92 to 1.00) · ·
most deprived: −0.01 to 13.47 21 419   1.00 (0.95 to 1.04) · ·
Urbanisation level 85 790   
Predominantly urban 59 170 Reference 0.32 · ·   · ·
Mid- urban 13 033 0.96 (0.92 to 1.00) ·   ·
Predominantly rural 13 587 1.02 (0.97 to 1.06) ·   ·
*Median number of palliative care unit beds/100 deaths- year, per health region.
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with higher risk of receiving ACCEoL. These findings 
might be due to higher complexity of cases treated in 
cancer centres or easier access to antineoplastic treat-
ments and clinical trials when MOD exists at the hospital 
of admission. On the other hand, and in contrast with what 
literature reports,28 our study showed no association of 
availability of hPCS and reduction of ACCEoL. This result 
might be influenced by the fact that hospitals with hPCS 
are often those with a case mix of more complex patients, 
with higher risk of ACCEoL. It also may be because hPCS 
effect was measured at a hospital- level, since the HMD 
did not provide individual data on hPCS intervention (we 
could only measure the existence of hPCS at the hospital 
where a given patient died). Moreover, late referral or 
limited human resources in hPCS could hinder their 
impact on ACCEoL. There was no effect of region- level 
characteristics on ACCEoL, as opposed to other studies.7
This is a robust nationwide study that used multivariate 
methods to control for confounders at different levels. 
However, the use of routinely- collected data generated 
for administrative purposes does not allow to conclude 
to what extent the ACCEoL was adequate or inadequate 
for each individual, as the HMD does not contain the 
cause of death or the setting of the anticancer treatment 
(curative vs palliative). To overcome this limitation, we 
planned the subgroup analysis of metastatic disease as 
a sensitivity analysis, since the treatment intent in these 
patients is mostly palliative. We expanded the Earle et al’s 
framework,6 but emergency department visits were not 
included in this study, thus the prevalence of ACCEoL 
could be even higher than we estimated (measurement 
bias). In contrast, the study was restricted to people who 
died in hospital, who are likely to receive higher ACCEoL 
than those who died elsewhere (selection bias).
CONCLUSIONS
This study unravelled important data on ACCEoL and 
associated risk factors, expanding the earlier framework 
for measuring ACCEoL. We confirmed that clinical factors 
related with a better understanding of disease course are 
associated with ACCEoL reduction. In contrast, we iden-
tified groups of patients at increased risk for ACCEoL 
such as patients with more comorbidities, gastrointestinal 
and haematological malignancies. Therefore, clinicians 
should seek for better integration of prognostic estima-
tions with adequate timing for anticipated discussion 
of patients and families’ preferences and expectations, 
particularly within the high- risk groups identified by our 
study. Efforts should be made for empowerment and rein-
forcement of the growing number of hospital and home 
PCS, with human resources, earlier referral and integra-
tion into a comprehensive cancer care plan, mainly in 
cancer centres and hospitals with MOD. The study recog-
nised need for further research on the impact of the 
social and clinical community support on hospitalisation 
rates, determinants for surgery procedure, management 
of haematological malignancies at the EoL, and higher 
ACCEoL in patients who deceased at cancer centres or 
hospitals with MOD.
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